<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537574</url>
  </required_header>
  <id_info>
    <org_study_id>ALK6428-A301</org_study_id>
    <nct_id>NCT02537574</nct_id>
  </id_info>
  <brief_title>Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)</brief_title>
  <official_title>A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, effectiveness and tolerance of low doses of oral
      naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection
      of VIVITROL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">January 9, 2017</completion_date>
  <primary_completion_date type="Actual">October 27, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who receive and tolerate a VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
    <description>Demonstrated by mild COWS assessment of less than or equal to 12 or SOWS assessment of less than or equal to 10 opioid withdrawal symptoms following VIVITROL administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of days with COWS peak score of less than or equal to 12 during the treatment period prior to the VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean peak COWS score during treatment period prior to VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) COWS score during the treatment period prior to VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean score for desire of opioids during treatment period prior to VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
    <description>Using a Visual Analog Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Effects</measure>
    <time_frame>Up to 92 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve SOWS score during the treatment period prior to the VIVITROL injection</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Opioid Use Disorder</condition>
  <arm_group>
    <arm_group_label>NTX/BUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral naltrexone + sublingual buprenorphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX/PBO-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral naltrexone + sublingual placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO-N/PBO-B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo naltrexone + sublingual placebo buprenorphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTX/BUP</intervention_name>
    <description>Daily doses</description>
    <arm_group_label>NTX/BUP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTX/PBO-B</intervention_name>
    <description>Daily doses</description>
    <arm_group_label>NTX/PBO-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBO-N/PBO-B</intervention_name>
    <description>Daily doses</description>
    <arm_group_label>PBO-N/PBO-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent

          -  Willing and able to provide government-issued identification

          -  Has a BMI of 18.0-40.0 kg/m^2

          -  Has a physiologic dependence on opioids

          -  Is voluntarily seeking treatment for opioid use disorder and willing to completely
             withdraw from his/her opioid use throughout the study with desire for or motivation
             for antagonist therapy

          -  Wiling to abide by the contraception requirements for the duration of the study

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Is pregnant, planning to become pregnant or breastfeeding during the study

          -  Has used Buprenorphine within 7 days prior to randomization

          -  Has used Methadone within 14 days prior to randomization

          -  Has a history of VIVITROL use within 90 days prior to screening or has used oral
             naltrexone within 14 days prior to randomization

          -  Has a history of seizures or has received anticonvulsant therapy within the past 5
             years

          -  Has a condition, disease state, or previous medical history that would preclude safe
             participation in the study or affect the ability to adhere to the protocol visit
             schedule, requirements, or assessments

          -  Has a current diagnosis of schizoaffective disorder, bipolar disorder, or untreated
             and unstable major depressive disorder

          -  Is currently physiologically dependent on any psychoactive substance (except opioids,
             caffeine, or nicotine) requiring medical intervention for detoxification

          -  Has a history of hypersensitivity or adverse reaction to Buprenorphine, Naltrexone, or
             Naloxone

          -  Has a history of more than 3 unsuccessful inpatient or medically assisted outpatient
             opioid detoxifications during his/her lifetime

          -  Has significant suicidal ideation or behavior within the past year

          -  Is currently participating, or has participated, in a clinical trial of an
             investigational drug, device, or biologics within 3 months prior to screening

          -  Has a history of accidental opioid drug overdose in the past 3 years whether or not
             medical treatment was sought or received

          -  Is court mandated to receive treatment for opioid use disorder

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria A. Sullivan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Country Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Shores Hospital</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRY Research</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Institute</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Research</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/ Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research, Inc.</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center, LLC</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania - Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Psychiatric Institute and Clinic of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insite Clinical Research</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <disposition_first_submitted>January 31, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2018</disposition_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alkermes</keyword>
  <keyword>Buprenorphine</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Vivitrol</keyword>
  <keyword>Opioid Use</keyword>
  <keyword>Opiates</keyword>
  <keyword>Dependence</keyword>
  <keyword>Abuse</keyword>
  <keyword>Heroin</keyword>
  <keyword>Painkillers</keyword>
  <keyword>Substance Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

